Collegium Pharmaceutical, Inc. (COLL)
24.29
+0.29
(+1.21%)
USD |
NASDAQ |
Sep 02, 16:00
24.29
0.00 (0.00%)
After-Hours: 20:00
Collegium Pharmaceutical Research and Development Expense (Annual) : 0.00 for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| December 31, 2022 | 1.299M |
| December 31, 2021 | 7.715M |
| December 31, 2020 | 9.772M |
| December 31, 2019 | 10.34M |
| Date | Value |
|---|---|
| December 31, 2018 | 8.661M |
| December 31, 2017 | 8.572M |
| December 31, 2016 | 14.95M |
| December 31, 2015 | 7.975M |
| December 31, 2014 | 14.77M |
| December 31, 2013 | 13.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Innoviva, Inc. | 30.60M |
| Zevra Therapeutics, Inc. | 12.55M |
| Supernus Pharmaceuticals, Inc. | 104.13M |
| Indivior Pharmaceuticals, Inc. | 80.00M |
| Crinetics Pharmaceuticals, Inc. | 328.17M |